Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovaBridge BiosciencesNBP +2.94%30 EV-to-EBITDA is 0.06 as of Aug. 08, 2026, which is 75% below its 10-year median of 0.24. GuruFocus rates NBP with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 409 Biotechnology companies, NovaBridge Biosciences ranks better than 94.13% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NovaBridge Biosciences's enterprise value is $-5.39 Mil.
NovaBridge Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-93.84 Mil. Therefore, NovaBridge Biosciences's EV-to-EBITDA for today is 0.06.
The historical rank and industry rank for NovaBridge Biosciences's EV-to-EBITDA or its related term are showing as below:
NBP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.83 Med: 0.24 Max: 47.7
Current: 0.06
During the past 9 years, the highest EV-to-EBITDA of NovaBridge Biosciences was 47.70. The lowest was -24.83. And the median was 0.24.
NBP's EV-to-EBITDA is ranked better than 94.13% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs NBP: 0.06
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NovaBridge Biosciences's PE Ratio (TTM) for today is calculated as:
NovaBridge Biosciences's share price for today is $1.74.
NovaBridge Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.483.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NovaBridge Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovaBridge Biosciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NovaBridge Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NovaBridge Biosciences's EV-to-EBITDA falls into.
NovaBridge Biosciences's current Enterprise Value is $-5.39 Mil.
NovaBridge Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-93.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovaBridge Biosciences (NBP) has a EV-to-EBITDA of 0.06 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NovaBridge Biosciences. This is 75% below median its historical median of 0.24. According to the industry distribution chart, NovaBridge Biosciences ranks #24 out of 409 companies in the Biotechnology industry, placing it in the top 5.9%.
Is NovaBridge Biosciences' EV-to-EBITDA too high?
NovaBridge Biosciences' current EV-to-EBITDA of 0.06 is 75% below median its 10-year median of 0.24. The Biotechnology industry median EV-to-EBITDA is 12.99. NovaBridge Biosciences' value of 0.06 is 99.5% below this industry median. Based on the distribution chart, NovaBridge Biosciences ranks #24 out of 409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NovaBridge Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' EV-to-EBITDA compare to KROS and SLNCF?
According to the Biotechnology industry distribution chart, NovaBridge Biosciences ranks #24 out of 409 companies for EV-to-EBITDA. This places NovaBridge Biosciences in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.99. NovaBridge Biosciences' value of 0.06 is 99.5% below this benchmark. While the company's 10-year median is 0.24 vs. the industry median of 12.99, NovaBridge Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NovaBridge Biosciences's current EV-to-EBITDA of 0.06 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NovaBridge Biosciences. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovaBridge Biosciences's current EV-to-EBITDA is 0.06, which is 75% below median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
NovaBridge Biosciences (NBP) has a current EV-to-EBITDA of 0.06. The current EV-to-EBITDA is 0.06, which is 75% below median its 10-year median of 0.24 and 99.5% below the Biotechnology industry median of 12.99. NovaBridge Biosciences' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NovaBridge Biosciences (NBP), the current EV-to-EBITDA is 0.06 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
30GF Score
Get the complete analysis for NBP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NBP has been successfully added to your 
